But I am not making an arguement that the FDA - once the data are actually in hand - will do anything other than grant approval to do human testing of Flucide.
ONLY that because the FDA approval has not YET come, that the shareprices here did not increase more dramatically. The results reported today - while very positive (IMO) - are alreaady largely factored into the market perception of where this stock should be valued.
This is an important step on the path to getting FDA approval. This step is recognized by the increase in shareprice we do so today.
However - since it is only a step on the pathway - and not reaching the endpoint of that pathway - don't expect to see much more at present.
IF - on the other hand - some toxicity had been noticed from these last tests - THEN we would have seen a sharp drop in shareprice in response.
News 
Market Data 
Discover 
AI
